Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS

Y Intercept Hong Kong Ltd reduced its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 53.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 48,545 shares of the company’s stock after selling 56,333 shares during the period. Y Intercept Hong Kong Ltd owned about 0.16% of Keros Therapeutics worth $768,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its stake in Keros Therapeutics by 8.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after buying an additional 988 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Keros Therapeutics by 29.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock valued at $110,000 after acquiring an additional 1,892 shares during the period. CWM LLC raised its position in Keros Therapeutics by 45.4% in the 3rd quarter. CWM LLC now owns 7,271 shares of the company’s stock valued at $115,000 after purchasing an additional 2,271 shares during the last quarter. Finally, Farther Finance Advisors LLC acquired a new stake in Keros Therapeutics during the 3rd quarter worth $47,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KROS. Oppenheimer reaffirmed an “outperform” rating and issued a $27.00 target price (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Wells Fargo & Company reduced their price objective on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Zacks Research downgraded Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. TD Cowen raised Keros Therapeutics to a “hold” rating in a report on Friday, December 19th. Finally, Wedbush increased their price target on Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Keros Therapeutics currently has an average rating of “Hold” and a consensus price target of $22.29.

Keros Therapeutics Price Performance

KROS opened at $18.40 on Tuesday. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $22.55. The stock has a market capitalization of $560.57 million, a P/E ratio of 11.95 and a beta of 0.89. The business has a 50 day simple moving average of $19.52 and a 200-day simple moving average of $16.81.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The firm had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $4.22 million. During the same quarter in the prior year, the business posted ($1.41) earnings per share. Keros Therapeutics’s revenue was up 3585.6% compared to the same quarter last year. Research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.